Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015

NEW YORK, March 30, 2015 /PRNewswire/ -- Check-Cap Ltd. (NASDAQ: CHEK), a clinical stage medical diagnostics company focused on the development of a preparation-free ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, announced today that its CEO, Guy Neev, will ring the closing bell of the March 31, 2015 trading day.  Neev and Check-Cap will participate in the closing bell ceremonies at NASDAQ to commemorate the company's initial public offering and simultaneous private placement which raised a total of $24 million in aggregate gross proceeds.

March is Colon Cancer Awareness Month in the United States.  Check-Cap, an innovator in colorectal cancer screening technology, will ring the bell on the final day of a month focused on patient education and national campaigns to encourage individuals to be screened.  Colorectal cancer is the second leading cause of cancer deaths in the United States, where only 50% of eligible patients go for their routine colon screenings.

"We look forward to commemorating our IPO, and more importantly, colon cancer awareness this week," said Check-Cap CEO Guy Neev.  "Screenings save lives, and Check-Cap is proud to be a part of critical innovation in cancer screening technology occurring around the world."

Check-Cap is a clinical stage medical diagnostics company that has developed an innovative solution for colorectal cancer screening. Offering a multi-disciplinary solution for imaging and screening the colon, the Check-Cap system includes an ingestible imaging capsule, a receiver and proprietary imaging software for data analysis.

The Check-Cap ingestible imaging capsule is rooted in technology that does not require bowel preparation or invasive procedures, like other ingestible capsules or the traditional colonoscopy.  As a result, the Check-Cap system eliminates the uncomfortable pre-screening process which is a major reason why 50% of Americans avoid this critical, lifesaving test. 

Offering a non-invasive alternative to conventional colon screening, Check Cap's innovative technology allows the patient to simply swallow the capsule and continue his or her daily routine while the capsule travels painlessly through the colon.  X-ray technology provides 3D imaging of the colon that is designed to detect significant polyps with the same accuracy as a traditional colonoscopy.

About Check-Cap

Check-Cap is a clinical stage medical diagnostics company focused on the development of gastrointestinal imaging devices. The Company's lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and clinically-significant pre-cancerous polyps that utilizes proprietary, ultra-low-energy X-ray-based measurement technology to safely generate high-resolution, 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. This solution is designed to increase compliance with screening recommendations. The Check-Cap imaging system is not cleared for marketing in any jurisdiction.

For more information, please visit: http://www.check-cap.com/

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.  Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.  For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.  The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

CONTACTS:

Investors
David Carey
Lazar Partners Ltd.
212-867-1768
[email protected]

Media
Jennifer Wlach
Mercury LLC
[email protected]

John Cpin
Mercury LLC
[email protected]

SOURCE Check-Cap Ltd.

Related Links

http://www.check-cap.com